Related Experiment Video
Updated: Jul 19, 2026

07:48
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
Published on: September 22, 2011
A novel, high stringency selection system allows screening of few clones for high protein expression
H J M van Blokland1, T H J Kwaks, R G A B Sewalt
1ChromaGenics, Kruislaan 406, 1098 SM Amsterdam, The Netherlands.
Journal of Biotechnology
|November 10, 2006
Summary
Developing high-protein producing mammalian cell lines is challenging. A novel stringent selection system, coupled with anti-repressor elements, enables the rapid creation of rare, high-producing clones for biopharmaceutical applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Cell Line Development
Background:
- Mammalian cell line development for high protein production often requires screening numerous clones due to low selection stringency.
- Existing methods result in many low-producing clones, necessitating extensive screening efforts.
Purpose of the Study:
- To design and validate a novel, highly stringent selection system for creating rare, high-protein producing mammalian cell lines.
- To improve the efficiency of generating productive cell lines for biopharmaceutical applications.
Main Methods:
- A bicistronic mRNA strategy was employed, placing a selection marker with attenuated translation upstream of the gene of interest with optimal translation.
- The system's stringency was tested, and its efficacy was enhanced by incorporating anti-repressor elements to boost promoter activity.
Main Results:
- The novel selection system demonstrated high stringency, yielding very few clones.
- The incorporation of anti-repressor elements successfully induced the formation of clones with significantly high protein expression levels.
Conclusions:
- This stringent selection system, when combined with anti-repressor elements, is a valuable tool for rapidly generating highly productive mammalian cell lines.
- The approach offers a more efficient method for biomanufacturing by reducing the need for extensive clone screening.

